Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice

Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice

Clinical anti-drug-antibody (ADA) responses represent a substantial obstacle to the development of efficacious therapeutic antibodies. The enhanced ADA production against the idiotype (Id) often displayed by cancer immunotherapy antibodies (CitAbs) can lead to exposure loss and subsequently affect a...

Full description

Bibliographic Details
Main Authors: Jerome Egli, Stefan Heiler, Felix Weber, Guido Steiner, Timo Schwandt, Katharine Bray-French, Christian Klein, Sebastian Fenn, Gregor P. Lotz, Eugenia Opolka-Hoffmann, Thomas E. Kraft, Laetitia Petersen, Rebecca Moser, Jonathan DeGeer, Michel Siegel, Daniela Finke, Juliana Bessa, Antonio Iglesias
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:mAbs
Subjects:
ADA
idiotype
immunogenicity
linked-antigen tolerance
FcRn
Fc-tolerance
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2022.2143009

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2022.2143009

Similar Items